We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+7.14%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$572M
AUM Growth
-$9.61M
Cap. Flow
-$82.5M
Cap. Flow %
-14.43%
Top 10 Hldgs %
86.44%
Holding
30
New
4
Increased
5
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$18M
2
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$12.8M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$12.5M
4
XNCR icon
Xencor
XNCR
+$7.03M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$5.73M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$27.6M
2
EXEL icon
Exelixis
EXEL
+$14.6M
3
ARRY
Array Biopharma Inc
ARRY
+$11.8M
4
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$10.3M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.03M

Sector Composition

Rank Sector Weight
1 Healthcare 76.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
1
Ligand Pharmaceuticals
LGND
$5.87B
$138M 24.17%
4,209,734
-845,591
-17% -$27.6M
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$686M
$111M 19.45%
11,433,325
+2,005,428
+21% +$18M
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
$45.1M 7.9%
7,796,516
+2,418,900
+45% +$12.5M
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
$37.8M 6.62%
7,553,089
-2,166,500
-22% -$11.8M
OMED
5
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$32.2M 5.63%
1,090,478
+698,678
+178% +$12.8M
GYRE icon
6
Gyre Therapeutics
GYRE
$634M
$25.6M 4.48%
7,837
– –
RIGL icon
7
Rigel Pharmaceuticals
RIGL
$679M
$22.6M 3.96%
794,322
-178,748
-18% -$5.25M
CASC
8
DELISTED
Cascadian Therapeutics, Inc.
CASC
$15.8M 2.77%
1,500,296
+21,500
+1% +$240K
CYTK icon
9
Cytokinetics
CYTK
$10.6B
$15.4M 2.69%
2,368,905
+650,000
+38% +$4.27M
QLTI
10
DELISTED
QLT Inc
QLTI
$13.2M 2.31%
2,370,263
– –
RCPT
11
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$9.18M 1.61%
316,692
-3,308
-1% -$88.6K
TBRA
12
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$7.91M 1.38%
184,343
– –
FPRX
13
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$7.74M 1.35%
+461,000
New +$5.73M
XNCR icon
14
Xencor
XNCR
$1.5B
$7.5M 1.31%
+820,000
New +$7.03M
ARQL
15
DELISTED
Arqule Inc
ARQL
$6.07M 1.06%
2,824,387
-110,800
-4% -$250K
PTN
16
Palatin Technologies
PTN
$13.8M
$3.82M 0.67%
4,160
– –
BIND
17
DELISTED
BIND THERAPEUTICS INC
BIND
$2.26M 0.4%
+150,000
New +$1.91M
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.23M 0.39%
134,317
-411,055
-75% -$7.03M
SPHS
19
DELISTED
Sophiris Bio, Inc.
SPHS
$2.22M 0.39%
600,000
– –
RGLS
20
DELISTED
Regulus Therapeutics
RGLS
$1.73M 0.3%
1,947
– –
KIN
21
DELISTED
Kindred Biosciences, Inc.
KIN
$577K 0.1%
+51,788
New +$617K
PRTK
22
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$504K 0.09%
12,500
– –
AGIO icon
23
Agios Pharmaceuticals
AGIO
$1.86B
$47K 0.01%
196,996
– –
ANTH
24
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$17K ﹤0.01%
69,953
– –
EXEL icon
25
Exelixis
EXEL
$13.4B
– –
-2,502,256
Closed -$14.6M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2013 Portfolio in Review

As of Q4 2013, BVF Inc held 30 positions worth $572M, down 1.7% from $581M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

BVF Inc withdrew a net $82.5M in Q4 2013, closing 4 positions and reducing 6 holdings. Its most notable exit was Exelixis, an estimated $14.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 79% a quarter earlier.

Against the trend, BVF Inc opened a new position in Xencor worth $7.5M.

  • BVF Inc's largest Q4 2013 buy was Xencor: 820,000 shares worth $7.5M.
  • BVF Inc added most to Ironwood Pharmaceuticals in Q4 2013, an estimated $18M increase.
  • BVF Inc's biggest Q4 2013 reduction was Ligand Pharmaceuticals, cutting an estimated $27.6M.
  • BVF Inc fully exited Exelixis in Q4 2013, selling an estimated $14.6M.
  • BVF Inc's ten largest holdings make up 86% of its $572M portfolio in Q4 2013.
  • BVF Inc opened 4 new positions and closed 4 in Q4 2013.
  • BVF Inc's portfolio value fell 1.7% quarter-over-quarter to $572M.

Based on BVF Inc's 13F filing for Q4 2013, filed 14 Feb 2014.